Skip to main content

Table 2 Effect of T3 molecules on cell viability of different breast cancer cell lines

From: Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E

T3 form

Breast cancer cells

IC50 [μM] (time of treatments)

References

δ-T3

MDA-MB-231a

22.6h (48 h)

(Guthrie et al. 1997)

MCF7b

5.5h (48 h)

CL-S1d

7h (5 days)

(McIntyre et al. 2000)

−SAe

4h (5 days)

+SAf

3h (5 days)

MDA-MB-231

10h (48 h)

(Elangovan et al. 2008)

MDA-MB-231

20h (72 h)

SKBr3g

45.6h (24 h)

(Pierpaoli et al. 2010)

SKBr3g

31.5h (48 h)

γ-T3

MDA-MB-231a

73h (48 h)

(Guthrie et al. 1997)

MCF7b

4.87h (48 h)

CL-S1d

8h (5 days)

(McIntyre et al. 2000)

−SAe

5h (5 days)

+SAf

4h (5 days)

SKBr3g

55.2h (24 h)

(Pierpaoli et al. 2010)

SKBr3g

34h (48 h)

α-T3

MDA-MB-231a

>100h (24 h)

(Guthrie et al. 1997)

MCF7b

14.2a (48 h)

TRF

4T1c

8 ug/mlh (72 h)

(Hafid et al. 2009)

  1. TRF standardized tocotrienol-rich fraction (TRF)
  2. a MDA-MB-231 Human epithelial breast cancer cell line, isolated by pleural effusion from mammary gland, low erbB-2 receptor-expressing (HTB-30; American type culture collection (ATCC), Manassas, VA)
  3. b MCF7 first cell line derived from a pleural effusion of a post menopausal 69 years patient with metastatic breast cancer. This is the most widely used and best characterized of all human breast cancer cell lines
  4. c 4T1 mouse mammary tumor cell line; this is one of few breast cancer cells capable to metastasize efficiently to sites affected in human breast cancer
  5. d CL-S1 Preneoplastic non-malignant mouse mammary epithelial cells
  6. eSA murine mammary adenocarcinoma (HTB-30; American rype culture collection (ATCC), Manassas, VA)
  7. f+SA highly malignant murine cells isolated from animals that spontaneously develop breast cancer (HTB-30; American Type Culture Collection (ATCC), Manassas, VA)
  8. g SKBr3 Her-2/neu positive human mammary carcinoma cell (HTB-30; American type culture collection (ATCC), Manassas, VA)
  9. hInhibition of viability assessed by MTT test or equivalent test